Quantum-Si (QSI) to Release Earnings on Thursday

Quantum-Si (NASDAQ:QSI) is expected to post its quarterly earnings results after the market closes on Thursday, March 6th. Analysts expect Quantum-Si to post earnings of ($0.18) per share and revenue of $1.23 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Quantum-Si Stock Up 2.1 %

NASDAQ QSI opened at $1.49 on Thursday. The business’s fifty day simple moving average is $2.23 and its 200-day simple moving average is $1.43. The firm has a market cap of $212.64 million, a PE ratio of -2.33 and a beta of 2.70. Quantum-Si has a 52 week low of $0.61 and a 52 week high of $5.77.

Analyst Ratings Changes

QSI has been the subject of a number of recent analyst reports. Canaccord Genuity Group cut their price objective on Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a research report on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and set a $5.50 price objective on shares of Quantum-Si in a research report on Tuesday, January 14th. Finally, Alliance Global Partners initiated coverage on Quantum-Si in a research report on Friday, February 7th. They issued a “buy” rating and a $3.75 target price for the company.

Insider Buying and Selling at Quantum-Si

In other news, Director Jonathan M. Rothberg sold 3,506,267 shares of Quantum-Si stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $3.34, for a total value of $11,710,931.78. Following the completion of the transaction, the director now owns 1,250,000 shares in the company, valued at approximately $4,175,000. This trade represents a 73.72 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 30.04% of the stock is currently owned by corporate insiders.

About Quantum-Si

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments.